High Prevalence of Proarrhythmic Events in Patients With History of Atrial Fibrillation Undergoing a Rhythm Control Strategy: A Retrospective Study.

Conclusions: Secondary prevention of AF relapses by means of drugs suitable for accomplishing rhythm control strategy exposes the patients to incumbent risk of proarrhythmic events. Thus, the choice to avoid some varieties of antiarrhythmics with marked proarrhythmic potential (class IC drugs, sotalol, quinidine) appears to be warranted. PMID: 31019629 [PubMed]
Source: Clin Med Res - Category: Research Authors: Tags: J Clin Med Res Source Type: research

Related Links:

Review in-depth clinical information, latest medical news, and guidelines about cardiac arrhythmias, including atrial fibrillation, paroxysmal tachycardia, ventricular tachycardia, and ventricular fibrillation. Read about diagnostic tests for arrhythmia and arrhythmia management.
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Resource Center Source Type: news
ConclusionsArrhythmias, including clinically significant abnormal rhythms, were common. Tachyarrhythmias were more frequent during dialysis and the immediate postdialytic period. The relevance of these findings to clinical outcomes requires additional study.
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
BioSig Technologies and Mayo Clinic have joined forces once again, this time to develop a new product pipeline to support some of the more advanced features of BioSig's Pure EP System. Samuel Asirvatham, MD, Mayo Clinic's vice-chair of innovation and medical director of the electrophysiology (EP) laboratory, will lead the new development program. The company previously signed a 10-year collaboration agreement with Mayo Clinic in March 2017. "The new product that we intend to develop under the latest licensing will seek to significantly advance the current arrhythmia treatments," said Kenne...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
Publication date: Available online 4 September 2019Source: Pharmacological ResearchAuthor(s): Enrico Paolini, Giulia Stronati, Federico Guerra, Alessandro CapucciAbstractOver the last 35 years, flecainide proved itself one of the most commonly used arrhythmic drugs, expanding its original indication for ventricular arrhythmias and results nowadays as the cornerstone of the rhythm control strategy in atrial fibrillation management of patients without structural heart disease. While the increased mortality associated with flecainide in the Cardiac Arrhythmia Suppression Trial (CAST) still casts his shadow over flecainide cli...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
AbstractDespite major therapeutic advances over the last decades, complex supraventricular and ventricular arrhythmias (VAs), particularly in the emergency setting or during revascularization for acute myocardial infarction (AMI), remain an important clinical problem. Although the incidence of VAs has declined in the hospital phase of acute coronary syndromes (ACS), mainly due to prompt revascularization and optimal medical therapy, still up to 6% patients with ACS develop ventricular tachycardia and/or ventricular fibrillation within the first hours of ACS symptoms. Despite sustained VAs being perceived predictors of wors...
Source: Europace - Category: Cardiology Source Type: research
ConclusionsDue to worse outcomes with arrhythmias, there is a need for better screening and follow-up of ESLD patients for dysrhythmias.
Source: Heart and Lung: The Journal of Acute and Critical Care - Category: Respiratory Medicine Source Type: research
Background: The prevalence of atrial fibrillation (AF) has not been well described in young patients with inherited heart diseases such as the inherited cardiomyopathies: hypertrophic cardiomyopathy (HCM), familial dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), left ventricular non-compaction (LVNC); or inherited arrhythmia syndromes including long QT syndrome (LQTS), Brugada syndrome (BrS) or catecholaminergic polymorphic ventricular tachycardia (CPVT).
Source: Heart, Lung and Circulation - Category: Cardiology Authors: Tags: 455 Source Type: research
Stereotaxis, a company that has developed robotic magnetic navigation technology to deliver catheters to the heart during ablation procedures, is introducing its latest generation system. The new Stereotaxis Genesis RMN platform features smaller magn...
Source: Medgadget - Category: Medical Devices Authors: Tags: Cardiology Radiology Source Type: blogs
BioSig Technologies has developed the PURE EP electrophysiology information system, a product that aims to provide better tools for doctors who are treating potentially deadly arrhythmias. The computerized system is used to process electrophysiologic...
Source: Medgadget - Category: Medical Devices Authors: Tags: Cardiology Critical Care Exclusive Source Type: blogs
CONCLUSION: Findings from the review suggest that long-term, continuous, uninterrupted monitoring with Zio results in longer patient wear times and higher cardiac arrhythmia detection rates compared with outcomes reported in previous reviews of short-duration (24-48 hours) cardiac rhythm recording studies. PMID: 31045463 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Amiodarone | Arrhythmia | Atrial Fibrillation | Beta-Blockers | Cardiology | Heart | Research | Study | Ventricular Tachycardia